June 19, 2025

GLP-1 Use Reduces Opioid, Pain, Fatigue Burden in Fibromyalgia

At the EULAR 2025 Congress, researchers reported that GLP-1 receptor agonists were linked to reduced opioid use, pain, and fatigue in fibromyalgia patients based on a large real-world analysis.

Conexiant

June 17, 2025

Aconitine Tames Joints, Protects Bone

At EULAR 2025, researchers presented data showing aconitine reduced bone erosion and increased regulatory T cells in a rheumatoid arthritis mouse model.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

January 08, 2025

Modified Consent May Aid Psychedelic Trials

Researchers at the University of California, San Francisco propose modifications to informed consent procedures in psychedelic drug trials, aiming to balance scientific rigor and ethical standards.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant

September 23, 2024

Muscle Relaxants: Limited Long-Term Benefit for Pain

Despite doubling of muscle relaxant prescriptions since 2005, new review finds limited evidence for long-term benefit in most chronic pain conditions.

Conexiant

February 11, 2025

Copper, Iron Levels Tied to Fibromyalgia

A Mendelian randomization study of 400,000 individuals revealed elevated copper increases risk while iron shows protective effects against fibromyalgia.

Conexiant

December 16, 2024

Arthritis Drugs Linked to Fracture Risk

Current gabapentinoid use in patients with inflammatory arthritis was associated with a 36% higher odds of fractures compared to remote use, with risks persisting across most dose levels and showing marked impact shortly after drug initiation.

Conexiant